Global Patent Index - EP 1060259 A2

EP 1060259 A2 2000-12-20 - NOVEL MEANS AND METHODS FOR THE PREPARATION AND ACTIVATION OF NUCLEOSIDE AND NUCLEOTIDE BASED DRUGS

Title (en)

NOVEL MEANS AND METHODS FOR THE PREPARATION AND ACTIVATION OF NUCLEOSIDE AND NUCLEOTIDE BASED DRUGS

Title (de)

NEUE MITTEL UND VERFAHREN FÜR DIE HERSTELLUNG UND AKTIVIERUNG VON ARZNEIEN, DIE AUF NUKLEOSIDEN UND NUKLEOTIDEN BASIEREN

Title (fr)

NOUVEAUX MOYENS ET METHODES DE PREPARATION ET D'ACTIVATION DE MEDICAMENTS A BASE DE NUCLEOSIDES ET DE NUCLEOTIDES

Publication

EP 1060259 A2 (EN)

Application

EP 99906232 A

Priority

  • EP 99906232 A
  • EP 9900945 W
  • EP 98102546 A

Abstract (en)

[origin: WO9941404A2] Described are novel means and methods for the preparation and activation of nucleoside and nucleotide based drugs. In particular, a method for the production of a polypeptide having or having enhanced kinase activity for a nucleoside or nucleotide analog is provided and polypeptides obtainable by said method. Described are also polynucleotides and vectors encoding said polypeptide obtainable by the method of the invention as well as to host cells transformed therewith. Furthermore, antibodies against said polypeptide are provided and pharmaceutical and diagnostic compositions as well as kits comprising proteins having kinase activity for a nucleoside or nucleotide analog or their encoding polynucleotides or vectors. Furthermore, the use of the before described proteins, polypeptides, polynucleotides, vectors and antibodies is provided for the preparation of pharmaceutical compositions for treating, preventing and/or delaying a disease related to viral infection or cancer. In addition, a method for identifying inhibitors of nucleoside or nucleotide kinases is described and methods for identifying nucleoside or nucleotide based prodrugs employing the above mentioned polypeptides, polynucleotides, vectors and host cells. Also provided are compounds identifiable by said methods as well as pharmaceutical and diagnostic compositions comprising said inhibitors. Moreover, the use of proteins and polypeptides having nucleoside or nucleotide kinase activity or their encoding polynucleotides or vectors is described for the preparation of nucleoside or nucleotide phosphates or analogs and derivatives thereof.

IPC 1-7 (main, further and additional classification)

C12P 21/00; A61K 38/43; A61K 39/00; C07K 14/245; C07K 14/39; C07K 14/435; C07K 16/00; C12N 1/11; C12N 1/19; C12N 1/21; C12N 5/10; C12N 15/63; C12P 21/08

IPC 8 full level (invention and additional information)

C12N 15/09 (2006.01); A61K 31/7088 (2006.01); A61K 38/43 (2006.01); A61K 39/00 (2006.01); A61K 48/00 (2006.01); A61P 31/12 (2006.01); A61P 31/18 (2006.01); C07K 14/245 (2006.01); C07K 14/39 (2006.01); C07K 14/435 (2006.01); C07K 16/00 (2006.01); C07K 16/40 (2006.01); C12N 1/11 (2006.01); C12N 1/15 (2006.01); C12N 1/19 (2006.01); C12N 1/21 (2006.01); C12N 5/10 (2006.01); C12N 9/12 (2006.01); C12N 15/63 (2006.01); C12P 21/00 (2006.01); C12P 21/08 (2006.01); A61K 38/00 (2006.01)

CPC (invention and additional information)

C12N 9/1229 (2013.01); A61K 38/00 (2013.01)

Citation (search report)

See references of WO 9941404A3

Designated contracting state (EPC)

AT BE CH DE DK FR GB IT LI NL SE

EPO simple patent family

WO 9941404 A2 19990819; WO 9941404 A3 19991028; CA 2319134 A1 19990819; EP 1060259 A2 20001220; JP 2002503479 A 20020205

INPADOC legal status


2005-01-05 [18D] DEEMED TO BE WITHDRAWN

- Effective date: 20040629

2003-06-25 [17Q] FIRST EXAMINATION REPORT

- Effective date: 20030508

2000-12-20 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 20000913

2000-12-20 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A2

- Designated State(s): AT BE CH DE DK FR GB IT LI NL SE